Retatrutide: Mechanism & Trial Results Retatrutide (LY3437943) is a triple agonist weight loss drug by Eli Lilly
It can also be easier for insurance companies to cover bariatric surgery due to it being a one-time, permanent solution for weight loss, rather than an ongoing medication
Weight loss was consistent and progressive, starting at 3.93% at three months and reaching 7.87% at twelve months. In addition, several case series studies have demonstrated benefits of GLP-1s in kidney and pancreas transplant recipients, including lowering blood glucose levels and providing renal protective effects. GLP-1 RAs would be advantageous in liver transplant recipients due to their renal clearance, avoiding interference with immunosuppressant drug metabolism
tirzepatide combines GLP-1 with GIP activity
Can I take Mounjaro or Zepbound while breastfeeding
From injuries and recovery to gut health, skin, and even muscle growth this episode simplifies what most people get confused about
